Latest market price
36.14
-0.25-0.69%
Earnings
Down 0.7% — Earnings due 2026-11-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 22.45 | EPS (ttm) | 1.61 | Insider Own | 1.54% | Shs Outstand | 236.29M | Perf Week | -2.27% |
| Market Cap | 8.54B | Forward P/E | 21.64 | EPS next Y | 1.67 | Insider Trans | — | Shs Float | 234.38M | Perf Month | -0.44% |
| Enterprise Value | 9.70B | PEG | 3.25 | EPS next Q | 0.40 | Short Float | 4.27% | Perf Quarter | -11.51% | ||
| Income | 355.00M | P/S | 15.73 | EPS this Y | 9.82% | Short Ratio | 4.34 | Perf Half Y | -8.51% | ||
| Sales | 543.00M | P/B | 1.90 | EPS next Y | 7.41% | ROA | 5.99% | Short Interest | 10.02M | Perf YTD | -0.06% |
| Book/sh | 19.04 | P/C | 174.25 | EPS next 5Y | 6.91% | ROE | 8.54% | 52W High | 43.62 -17.15% | Perf Year | 5.21% |
| Cash/sh | 0.21 | P/FCF | 19.81 | EPS past 3/5Y | — 21.21% | ROIC | 5.86% | 52W Low | 33.98 6.36% | Perf 3Y | 67.24% |
| Dividend Est. | 1.56 (4.32%) | EV/EBITDA | 18.50 | Sales past 3/5Y | 36.39% 22.07% | Gross Margin | 76.03% | Volatility | 2.10% 1.98% | Perf 5Y | 71.69% |
| Dividend TTM | 1.50 (4.16%) | EV/Sales | 17.86 | EPS Y/Y TTM | 34.17% | Oper. Margin | 63.19% | ATR (14) | 0.77 | Perf 10Y | 153.26% |
| Dividend Ex-Date | Sep 30, 2026 | Quick Ratio | 1.20 | Sales Y/Y TTM | 96.03% | Profit Margin | 65.40% | RSI (14) | 45.65 | Recom | 2.37 |
| Dividend Gr. 3/5Y | 6.80% 6.03% | Current Ratio | 1.20 | EPS Q/Q | 5.56% | SMA20 | -0.36% | Beta | 0.79 | Target Price | 43.88 |
| Payout | 85.87% | Debt/Eq | 0.27 | Sales Q/Q | 87.21% | SMA50 | -3.52% | Rel Volume | 2.19 | Prev Close | 36.39 |
| Employees | 43 | LT Debt/Eq | 0.20 | Earnings | Nov 05 | SMA200 | -7.33% | Avg Volume | 2.43M | Price | 36.14 |
| IPO Date | May 29, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.03% -3.28% | Net Debt/EBITDA | 2.21 | Volume | 5,326,613 | Change | -0.69% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Reiterated | Wells Fargo | Overweight | $44 → $43 |
| Oct-13-26 | Reiterated | Wedbush | Underperform | $26 → $44 |
| Oct-05-26 | Reiterated | Raymond James | Outperform | $43 → $42 |
| Oct-05-26 | Reiterated | BMO Capital | Outperform | $47 → $45 |
| Sep-01-26 | Reiterated | Wells Fargo | Overweight | $41 → $44 |
| Aug-14-26 | Downgrade | RBC Capital | Outperform → Sector Perform | $44 → $43 |
| Aug-10-26 | Reiterated | Cantor Fitzgerald | Neutral | $42 → $43 |
| Jun-16-26 | Resumed | Raymond James | Outperform | $39 → $43 |
| Jun-15-26 | Reiterated | BMO Capital | Outperform | $43 → $47 |
| May-29-26 | Reiterated | KeyBanc | Overweight | $40 → $46 |
Latest News· Times ET
Oct-31-26
Oct-31-2608:17AM
Oct-29-26
Oct-24-26
Oct-24-2607:15AM
Oct-22-26
04:00PM
Oct-16-26
Oct-16-2605:52AM
Oct-09-26
Oct-09-2606:26PM
10:35AM
Oct-05-26
Oct-05-2605:27AM
Oct-04-26
Oct-04-2604:14PM
Oct-02-26
Oct-02-2606:02PM
09:45AM
04:00AM
Sep-30-26
Sep-30-2612:15PM
Company
CareTrust REIT, Inc. operates as a self-managed, publicly traded real estate investment trust. The company specializes in the ownership, acquisition, development, and leasing of various healthcare properties, including skilled nursing facilities, seniors' housing complexes, and other related medical real estate. It maintains a broad, nationwide portfolio of assets, all under long-term net lease agreements with an expanding group of reputable operators. CareTrust REIT is actively pursuing strategic growth across the United States, leveraging both external investments and organic expansion opportunities.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 543 | 477 | 228 | 199 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 131 | 195 | 14 | 10 | — | — | — | — | — | |
| Gross Profit | 414 | 282 | 215 | 189 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | -5 | 0 | 28 | 21 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 74 | -38 | 63 | 52 | — | — | — | — | — | |
| Operating Income | 344 | 320 | 124 | 116 | — | — | — | — | — | |
| Interest Expense | 50 | 44 | 30 | 41 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 71 | 49 | 31 | -21 | — | — | — | — | — | |
| Net Income Before Taxes | 364 | 325 | 124 | 54 | — | — | — | — | — | |
| Income Taxes | 9 | 5 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 355 | 321 | 125 | 54 | — | — | — | — | — | |
| Net Income From Continuing Operations | 355 | 320 | 124 | 54 | — | — | — | — | — | |
| Net Income | 355 | 321 | 125 | 54 | — | — | — | — | — | |
| EPS (Recurring) | 1.61 | 1.57 | 0.81 | 0.50 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.61 | 1.57 | 0.81 | 0.50 | — | — | — | — | — | |
| EPS (Diluted) | 1.61 | 1.57 | 0.80 | 0.50 | — | — | — | — | — | |
| EBITDA | 524 | 462 | 212 | 146 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 22.45 | 23.03 | 33.81 | 44.76 | — | — | — | — | — | |
| Price To Sales Ratio | 15.57 | 15.46 | 18.39 | 11.92 | — | — | — | — | — | |
| Gross Margin | 76.24 | 59.12 | 94.30 | 94.97 | — | — | — | — | — | |
| Operating Margin | 63.35 | 67.09 | 54.39 | 58.29 | — | — | — | — | — | |
| Net Margin | 65.38 | 67.30 | 54.82 | 27.14 | — | — | — | — | — | |
| Shares Outstanding | 234 | 204 | 155 | 106 | — | — | — | — | — | |
| Market Capitalization | 8,457 | 7,377 | 4,193 | 2,372 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wagner William M | CFO and Treasurer | Sep 04 '24 | Sale | 29.80 | 35,000 | 1,043,000 | 257,439 | Sep 05 |
| Plumb Spencer G | Director | Mar 13 '20 | Buy | 12.77 | 1,500 | 19,155 | 12,721 | Mar 16 |
| SABIN GARY B | Director | Nov 16 '15 | Buy | 10.25 | 20,000 | 205,000 | 32,160 | Nov 16 |
| Sedgwick David M. | Vice President of Operations | Aug 13 '15 | Buy | 10.50 | 19,000 | 199,500 | 114,422 | Aug 17 |
| Wagner William M | CFO, Secretary and Treasurer | Aug 13 '15 | Buy | 10.50 | 35,000 | 367,500 | 112,635 | Aug 17 |
| Stapley Gregory K. | President, Chairman and CEO | Aug 13 '15 | Buy | 10.50 | 50,000 | 525,000 | 205,015 | Aug 17 |
| Kline Jon D | Director | Aug 13 '15 | Buy | 10.50 | 25,000 | 262,500 | 36,570 | Aug 17 |
| Sedgwick David M. | Vice President of Operations | May 31 '15 | Option Exercise | 0.00 | 5,485 | 0 | 56,071 | Jun 02 |
| Christensen Christopher R. | Director | Jan 13 '15 | Sale | 11.78 | 30,604 | 360,644 | 1,109,170 | Jan 15 |
| Christensen Christopher R. | Director | Jan 12 '15 | Sale | 11.75 | 80,509 | 945,594 | 1,139,774 | Jan 12 |
| Christensen Christopher R. | Director | Jan 09 '15 | Sale | 11.87 | 31,400 | 372,661 | 1,220,283 | Jan 12 |
| Christensen Christopher R. | Director | Jan 08 '15 | Sale | 11.90 | 62,487 | 743,370 | 1,251,683 | Jan 12 |
| Christensen Christopher R. | Director | Jan 07 '15 | Sale | 11.80 | 30,078 | 355,002 | 1,314,170 | Jan 07 |
| Christensen Christopher R. | Director | Jan 06 '15 | Sale | 11.63 | 58,221 | 677,110 | 1,344,248 | Jan 07 |
| Christensen Christopher R. | Director | Jan 05 '15 | Sale | 11.78 | 26,701 | 314,564 | 1,402,469 | Jan 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.